drugset / Trial / NCT00162643
PI Vs. NNRTI Based Therapy for HIV Advanced Disease
Phase 4
Unknown
300 enrolled
National Institute of Medical Sciences and Nutrition Salvador Zubiran
Instituto Mexicano del Seguro Social · collabNational Council of Science and Technology, Mexico · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Ritonavir boosted protease inhibitor based therapy will have equivalent antiviral efficacy over 48 weeks compared to NNRTI based therapy in patients who are antiretroviral therapy naïve and initiate therapy with CD4 counts ≤ 200/mm3.
Timeline
- Start
- 2004-12
- Primary completion
- —
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | — | — |
| Subject | Lopinavir | Other / unclassified | — | — |
| Background | Lamivudine | Other / unclassified | — | — |
| Background | Ritonavir | Other / unclassified | — | — |
| Background | Zidovudine | Small molecule | — | — |